J&J's Caplyta meets main goal of bipolar mania study
- Posted on September 21, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
J&J's Caplyta meets main goal of bipolar mania study
Sept 21 (Reuters) - Johnson & Johnson said on Monday its experimental use of Caplyta for bipolar mania met the main goal of a late-stage study, bringing the drug a step closer to expanding beyond its currently approved uses. J&J gained Caplyta through its $14.6 billion acquisition of Intra-Cellular Therapies last year to bolster its neuroscience business. • Caplyta significantly reduced symptoms
